Considering All Options: Pharma’s Wait-And-See Deals Might Have Peaked
Executive Summary
Over the past few years, as pharmaceutical companies pursued or invented ways to gain proximity to promising technologies and assets at lower cost and risk, option-based alliances steadily gained in popularity. But an analysis of alliance data from Elsevier’s Strategic Transactions suggests that use of this deal structure has declined since 2009.